{"id":1005468,"date":"2026-09-23T11:41:36","date_gmt":"2026-09-23T15:41:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/"},"modified":"2026-09-23T11:41:36","modified_gmt":"2026-09-23T15:41:36","slug":"capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/","title":{"rendered":"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position:inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\">CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS<\/p>\n<p>SAN FRANCISCO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Hagens Berman notifies investors in <strong>Capricor Therapeutics, Inc. (NASDAQ: CAPR)<\/strong> of the <strong>September 28, 2026 lead plaintiff deadline<\/strong> in the pending securities class action.<\/p>\n<p class=\"bwalignc\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fcapricor-therapeutics-inc-capr-securities-class-action&amp;esheet=54609436&amp;newsitemid=20260923807840&amp;lan=en-US&amp;anchor=Submit+Your+CAPR+Losses+To+HBSS&amp;index=1&amp;md5=6d4c8fea1218d3b32da62397f99a39f0\"><strong>Submit Your CAPR Losses To HBSS<\/strong><\/a><\/p>\n<p><strong>Key Details<\/strong><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Class Period: <\/b>Dec. 17, 2025 \u2013 July 26, 2026<\/li>\n<li><b>Lead Plaintiff Deadline: <\/b>Sept. 28, 2026<\/li>\n<li><strong>Visit:<\/strong><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fcapricor-therapeutics-inc-capr-securities-class-action&amp;esheet=54609436&amp;newsitemid=20260923807840&amp;lan=en-US&amp;anchor=www.hbsslaw.com%2Fcapr&amp;index=2&amp;md5=f52a36479f2962d14cb3dfc76c530f82\">www.hbsslaw.com\/capr<\/a><\/li>\n<li><b>Contact the Firm Now: <\/b><a rel=\"nofollow\" href=\"mailto:CAPR@hbsslaw.com\">CAPR@hbsslaw.com<\/a> \/ 844-916-0895<\/li>\n<li><strong>View our latest video summary of the allegations<\/strong>: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fyoutu.be%2F-lnVTKgV6as&amp;esheet=54609436&amp;newsitemid=20260923807840&amp;lan=en-US&amp;anchor=youtu.be%2F-lnVTKgV6as&amp;index=3&amp;md5=a878bd2e9b87ada5d8f9c2d078b90a61\"><strong>youtu.be\/-lnVTKgV6as<\/strong><\/a><\/li>\n<\/ul>\n<p><strong>Core Allegations<\/strong><\/p>\n<p>The lawsuit alleges that Capricor misrepresented clinical trial data and the regulatory pathway for its lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). Specifically, Defendants allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the FDA prior to resubmitting its Biologics License Application.<\/p>\n<p>On July 27, 2026, the FDA published briefing documents that revealed that Capricor made unagreed-upon post-hoc modifications to its SAP. The FDA stated that the HOPE-3 study \u201cdid not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months.\u201d Capricor shares immediately crashed roughly 64%.<\/p>\n<p>If you\u2019d like more information and answers to frequently asked questions about the Capricor case and the firm\u2019s investigation, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fcapricor-therapeutics-inc-capr-securities-class-action&amp;esheet=54609436&amp;newsitemid=20260923807840&amp;lan=en-US&amp;anchor=read+more+%C2%BB&amp;index=4&amp;md5=35d5e8ade91a9c8102e764b59a3d112b\">read more \u00bb<\/a><\/p>\n<p><b>Whistleblowers: <\/b>Persons with non-public information regarding Capricor should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at <strong>844-916-0895<\/strong> or email <a rel=\"nofollow\" href=\"mailto:CAPR@hbsslaw.com\">CAPR@hbsslaw.com<\/a>.<\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hbsslaw.com%2F&amp;esheet=54609436&amp;newsitemid=20260923807840&amp;lan=en-US&amp;anchor=About+Hagens+Berman&amp;index=5&amp;md5=0bd56034e38df462b10326f4d383c6e0\">About Hagens Berman<\/a><\/p>\n<p>Hagens Berman is a global plaintiffs\u2019 rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman\u2019s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hbsslaw.com%2F&amp;esheet=54609436&amp;newsitemid=20260923807840&amp;lan=en-US&amp;anchor=hbsslaw.com&amp;index=6&amp;md5=a3d5716c9e861913c9facfa1e1ed4067\">hbsslaw.com<\/a>. Follow the firm for updates and news at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&amp;esheet=54609436&amp;newsitemid=20260923807840&amp;lan=en-US&amp;anchor=%40ClassActionLaw&amp;index=7&amp;md5=13b7ead2af0dc031dd9bd3ff219e2a6c\">@ClassActionLaw<\/a>.<\/p>\n<p>Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260923807840\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260923807840\/en\/<\/a><\/span><\/p>\n<p>Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, <b>844-916-0895, <\/b><a rel=\"nofollow\" href=\"mailto:CAPR@hbsslaw.com\">CAPR@hbsslaw.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260923807840\/en\/2666927\/3\/11.25.2025-hbss-securities-unbold-space-1.0.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211;Hagens Berman notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the September 28, 2026 lead plaintiff deadline in the pending securities class action. Submit Your CAPR Losses To HBSS Key Details Class Period: Dec. 17, 2025 \u2013 July 26, 2026 Lead Plaintiff Deadline: Sept. 28, 2026 Visit:www.hbsslaw.com\/capr Contact the Firm Now: CAPR@hbsslaw.com \/ 844-916-0895 View our latest video summary of the allegations: youtu.be\/-lnVTKgV6as Core Allegations The lawsuit alleges that Capricor misrepresented clinical trial data and the regulatory pathway for its lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). Specifically, Defendants allegedly failed to disclose that they adopted changes to the pre-specified &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1005468","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211;Hagens Berman notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the September 28, 2026 lead plaintiff deadline in the pending securities class action. Submit Your CAPR Losses To HBSS Key Details Class Period: Dec. 17, 2025 \u2013 July 26, 2026 Lead Plaintiff Deadline: Sept. 28, 2026 Visit:www.hbsslaw.com\/capr Contact the Firm Now: CAPR@hbsslaw.com \/ 844-916-0895 View our latest video summary of the allegations: youtu.be\/-lnVTKgV6as Core Allegations The lawsuit alleges that Capricor misrepresented clinical trial data and the regulatory pathway for its lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). Specifically, Defendants allegedly failed to disclose that they adopted changes to the pre-specified &hellip; Continue reading &quot;CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-23T15:41:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS\",\"datePublished\":\"2026-09-23T15:41:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/\"},\"wordCount\":430,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/\",\"name\":\"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-09-23T15:41:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/","og_locale":"en_US","og_type":"article","og_title":"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS - Market Newsdesk","og_description":"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211;Hagens Berman notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the September 28, 2026 lead plaintiff deadline in the pending securities class action. Submit Your CAPR Losses To HBSS Key Details Class Period: Dec. 17, 2025 \u2013 July 26, 2026 Lead Plaintiff Deadline: Sept. 28, 2026 Visit:www.hbsslaw.com\/capr Contact the Firm Now: CAPR@hbsslaw.com \/ 844-916-0895 View our latest video summary of the allegations: youtu.be\/-lnVTKgV6as Core Allegations The lawsuit alleges that Capricor misrepresented clinical trial data and the regulatory pathway for its lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). Specifically, Defendants allegedly failed to disclose that they adopted changes to the pre-specified &hellip; Continue reading \"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-23T15:41:36+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS","datePublished":"2026-09-23T15:41:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/"},"wordCount":430,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/","name":"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-09-23T15:41:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260923807840r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-5-day-deadline-capricor-investors-have-opportunity-to-lead-class-action-hbss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action &#8211; HBSS"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1005468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1005468"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1005468\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1005468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1005468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1005468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}